Mirxes

Singapore, Singapore

Mirxes is an RNA technology company that develops blood-based miRNA test kits for early disease detection.

$91.1M raised

Jan 2026

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Mirxes raised?

Mirxes has raised $91.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.

Who are Mirxes's investors?

Mirxes's investors include Agency for Science, Technology and Research, Rock Springs Capital, Charoen Pokphand Group, EDBI, Mitsui & Co.

Where is Mirxes headquartered?

Mirxes is headquartered in Singapore, Singapore.

What does Mirxes do?

Mirxes is an RNA technology company that develops blood-based miRNA test kits for early disease detection.

What stage is Mirxes at?

Mirxes is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 29, 2026.

MLA

"Mirxes — Funding & Investors." VCBacked, January 29, 2026, https://www.vcbacked.co/company/mirxes. Accessed July 2, 2026.

APA

VCBacked. (2026). Mirxes — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/mirxes

Wikipedia (cite web)

{{cite web |title=Mirxes — Funding & Investors |url=https://www.vcbacked.co/company/mirxes |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 29, 2026.